Low-VOLTage Area-Guided Catheter Ablation and SVC Isolation for Persistent Atrial Fibrillation Using a Balloon-in-Basket Pulsed Field Ablation Catheter

Starting soon · Not applicable

Conditions studied: Atrial Fibrillation (AF)

In brief

The primary objective of this study is to determine whether low-voltage areas (LVA)-guided catheter ablation combined with superior vena cava (SVC) isolation and pulmonary vein isolation (PVI), performed using the balloon-in-basket Volt™ pulsed field ablation PFA system, is superior to PVI alone using same technology in reducing arrhythmia recurrence at 6 and 12 months in patients with persistent AF and detectable significant LVAs on three-dimensional electroanatomical mapping. Moreover, the study will investigate, in a separate randomized cohort, the effect of adding SVC isolation to PVI using the balloon-in-basket Volt™ PFA system, compared with PVI alone, in patients with persistent AF without detectable significant LVAs during three-dimensional electroanatomical mapping.

Key facts

Study ID

NCT07587541

Run by

University of Luebeck

People needed

618

Starts

2026-05-18

Expected to finish

2029-11-01

Last updated by the study team

2026-05-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must meet all the following criteria:
• Age ≥18 years
• Persistent AF, defined as continuous AF lasting at least 7 days
• Indication for catheter ablation according to the latest ESC guidelines
• Written informed consent

You may not qualify if…

• Participants will be excluded if any of the following criteria apply:
• Inability or unwillingness to provide informed consent
• Continuous AF duration duration of ≥2 years
• Documented atrial tachycardia or atrial flutter
• Previous left atrial catheter ablation or cardiac surgery
• Planned cardiac surgery within the first 3 months after inclusion
• History of heart transplantation, current listing for transplantation, or planned cardiac assist device implantation
• Severe mitral or aortic valvular disease, according to the ESC guidelines
• Platelet count <50,000 cells/mm³
• Body mass index >45 kg/m² or <18 kg/m²
• Untreated thyroid dysfunction (patients may be included once hypothyroidism or hyperthyroidism is adequately treated)
• Absolute contraindication to oral anticoagulation
• Any comorbidity that limits life expectancy to <1 year
• Active systemic infection (enrolment permitted after successful treatment)
• Women who are pregnant or breastfeeding
• Women of childbearing potential not using highly effective contraception (PEARL Index <1%)
• End-stage renal disease (GFR <15 ml/min/1.73 m2) or hepatic failure (Child Pugh C)
• Acutely decompensated heart failure (NYHA IV), inclusion is possible only after stabilization to a NYHA functional status better than IV
• Participation in another randomized controlled trial

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.